Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.

Thompson IM, Ankerst DP, Etzioni R, Wang T.

J Urol. 2008 Oct;180(4):1219-22. doi: 10.1016/j.juro.2008.07.089. Epub 2008 Aug 15. No abstract available.

PMID:
18707707
2.

Can we accurately identify men with low risk prostate cancer?

Neal DE.

J Urol. 2008 Oct;180(4):1217-8. doi: 10.1016/j.juro.2008.07.086. Epub 2008 Aug 15. No abstract available.

PMID:
18707718
3.

Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.

Walsh PC.

J Urol. 2009 Mar;181(3):1499; author reply 1499-500. doi: 10.1016/j.juro.2008.11.044. Epub 2009 Jan 20. No abstract available.

PMID:
19157429
4.

Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.

D'Amico AV, Chen MH.

J Clin Oncol. 2009 Aug 1;27(22):3575-6. doi: 10.1200/JCO.2009.22.6068. Epub 2009 Jun 8. No abstract available.

PMID:
19506151
6.

Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.

Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F.

Urology. 2009 May;73(5):1087-91. doi: 10.1016/j.urology.2008.10.048. Epub 2009 Feb 4.

PMID:
19195695
7.

Active surveillance for prostate cancer: has the time finally come?

Aragon-Ching JB.

J Clin Oncol. 2010 Jun 1;28(16):e265-6; author reply e267. doi: 10.1200/JCO.2010.28.1584. Epub 2010 Apr 20. No abstract available.

PMID:
20406916
8.

[PSA 2010--the beginning of a new era in early detection of prostate cancer].

Börgermann C, Sieverding M, Fornara P, Graefen M, Hammerer P, Semjonow A, Schröder F, Rübben H.

Urologe A. 2006 Sep;45 Suppl 4:127-33. German. No abstract available.

PMID:
16941115
9.

Estimated impact of the prostate cancer prevention trial on population mortality.

Zeliadt SB, Etzioni R, Kristal AR.

Cancer. 2005 Oct 1;104(7):1556-7; author reply 1557. No abstract available.

10.

Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.

San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC.

J Urol. 2011 Feb;185(2):471-6. doi: 10.1016/j.juro.2010.09.115. Epub 2010 Dec 17.

PMID:
21167525
11.

Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?

Klotz L.

Curr Urol Rep. 2007 Sep;8(5):341-4. Review. No abstract available.

PMID:
17880830
12.
13.

Is radiotherapy useful in node-positive prostate cancer patients after radical prostatectomy?

Van Poppel H.

Eur Urol. 2009 May;55(5):1012-3. doi: 10.1016/j.eururo.2009.02.015. Epub 2009 Feb 21. No abstract available.

PMID:
19261377
14.

Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.

Ercole B, Marietti SR, Fine J, Albertsen PC.

J Urol. 2008 Oct;180(4):1336-9; discussion 1340-1. doi: 10.1016/j.juro.2008.06.027. Epub 2008 Aug 15.

PMID:
18707696
15.
16.

The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.

Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia MS, Goodman P, Parnes H, Coltman CA Jr.

J Urol. 2008 Aug;180(2):544-7. doi: 10.1016/j.juro.2008.04.014. Epub 2008 Jun 11.

PMID:
18550097
17.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG.

J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17.

PMID:
18801539
18.

Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Albertson PC.

Eur Urol. 2009 Jun;55(6):1331-2. doi: 10.1016/j.eururo.2009.02.029. Epub 2009 Mar 6. No abstract available.

PMID:
19286304
19.

Assessing risk: does this patient have prostate cancer?

Carter HB.

J Natl Cancer Inst. 2006 Apr 19;98(8):506-7. No abstract available.

PMID:
16622114
20.

Targeting prostate cancer for focal destruction: can we find it?

Taneja SS, Tareen B.

Cancer. 2008 Oct 1;113(7):1500-1. doi: 10.1002/cncr.23780. No abstract available.

Supplemental Content

Support Center